
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
almost 30 years ago
The Year in Reviewalmost 30 years ago
Childhood Immunizations: Beyond HEDISalmost 30 years ago
Implementation of a Clinical Pathway for Cesarean Sectionalmost 30 years ago
Six HMOs in Search of a Study: Comments on Two Papers by Horn et alalmost 30 years ago
The Economic and Health-Related Quality of Life Impact of Epilepsyalmost 30 years ago
Telecomputing as a Tool to Increase Consumer Participation in Managed Carealmost 30 years ago
Disease Management: Has Anyone Managed to Make It Work?





